Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.56 +0.95 (+1.84%)

Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian ↗

March 28, 2025

Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates...

Via Stocktwits

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 ↗

March 28, 2025

The company is looking for drugs it can add to Wegovy to improve the amount of weight lost.

Via Investor's Business Daily

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk ↗

March 28, 2025

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.

Via Benzinga

Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%? ↗

March 28, 2025

Via The Motley Fool

Topics Earnings

Why Novo Nordisk Stock Dipped on Thursday ↗

March 27, 2025

Via The Motley Fool

1 Growth Stock Down 40% to Buy and Hold Forever ↗

March 27, 2025

Via The Motley Fool

Looking for growth without the hefty price tag? Consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO). ↗

March 27, 2025

Based on Fundamental Analysis it can be said that NYSE:NVO is a growth stock which is not overvalued.

Via Chartmill

Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam? ↗

March 26, 2025

Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.

Via Benzinga

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing ↗

March 26, 2025

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Via Benzinga

Is Novo Nordisk Stock a Buy? ↗

March 26, 2025

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

Via The Motley Fool

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗

March 25, 2025

Via Benzinga

Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves ↗

March 24, 2025

Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland...

Via Stocktwits

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

March 24, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped ↗

March 24, 2025

There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.

Via The Motley Fool

Motley Fool 2025 March Market Cap Showdown Championship ↗

March 24, 2025

Via The Motley Fool

Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech ↗

March 24, 2025

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity and diabetes treatment.

Via Benzinga

Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble. ↗

March 24, 2025

Novo Nordisk is now planning to take on Eli Lilly's experimental retatrutide, a triple agonist for weight loss and diabetes.

Via Investor's Business Daily

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

March 23, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

This Vanguard ETF Is Crushing the Market in 2025. Should You Buy? ↗

March 23, 2025

Via The Motley Fool

Topics ETFs

AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

March 23, 2025

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

Via MarketBeat

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly ↗

March 23, 2025

Via The Motley Fool

NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights

March 22, 2025

From Rosen Law Firm

Via Business Wire

Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

March 21, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Novo Nordisk, and Crocs and Encourages Investors to Contact the Firm

March 20, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

March 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Is This Simple Index Fund a Millionaire Maker? ↗

March 19, 2025

Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few opportunities and several challenges.

Via The Motley Fool

Is Novo Nordisk a No-Brainer Buy After It Dropped 40%? ↗

March 19, 2025

Via The Motley Fool

Why Novo Nordisk Stock Outpaced the Market on Tuesday ↗

March 18, 2025

Via The Motley Fool

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

March 18, 2025

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Via MarketBeat

UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension ↗

March 17, 2025

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with industry standards.

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today